Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis
Not intended for US and UK audiences BI 765423 has been developed…
Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted Therapeutics in Solid Tumors and Fibrosis
Company has built one of the largest proprietary extracellular matrix (ECM) datasets…
JASCAYD (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China
The approval marks the first new treatment option for people living with…
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis
The Company continues working with the third-party manufacturer to address recent FDA…
